Sweden Dermatology Drugs Market Analysis Report [2022-30]

Sweden Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Sweden Dermatology drugs market will reach a value of $xx Mn from $61.2 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Eczellon, Perrigo Sweden, and Meda AB. The market is driven by government regulations, the prevalence of dermatological disease, and reimbursement policies. The dermatology drug market in Sweden is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10SEPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Sweden AUTHOR: Dr. Vishwa Modhia

Buy Now

Sweden Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Sweden Dermatology drugs market will reach a value of $xx Mn from $61.2 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Different dermatological conditions may be more or less common in Sweden depending on factors like age, gender, lifestyle, and geography. However, atopic dermatitis (eczema), psoriasis, rosacea, and acne are some of the most prevalent skin conditions in Sweden. In Sweden, 10–20% of children and 1%–3% of adults have atopic dermatitis (eczema). Psoriasis affects approximately 2–3% of the Swedish population.

About 1–10% of Swedish adults are thought to have rosacea. An estimated 2,000 new cases of skin cancer are diagnosed each year in Sweden, making it one of the most prevalent cancer types. Public healthcare spending accounts for a sizable portion of Sweden's budget, with roughly 11% of the country's GDP going toward it. The Swedish healthcare system is regarded as one of the best in the world, with a strong emphasis on preventative care and on providing all citizens with high-quality care. Sweden is renowned for producing high-quality, reliable products.

sweden dermatology drugs market analysis

Market Dynamics

Market Growth Drivers

The rise in the number of skin disorders such as acne, eczema, and psoriasis has increased the demand for dermatology services in Sweden. The Swedish government has been investing in healthcare, which has created a favourable environment for the growth of the dermatology market. These factors are driving the dermatology market in Sweden.

Market Restraints

The requirements that a drug must fulfil in order to be eligible for reimbursement, such as being deemed necessary for the treatment of a specific condition, being cost-effective, and being approved for use in Sweden, may result in higher out-of-pocket expenses for patients. This will limit the use of dermatological drugs in Sweden.

Competitive Landscape

Key Players

Meda AB (SWE)
Perrigo Sweden AB (SWE)
Eczellon AB (SWE)
FOU Pharma AB (SWE)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Swedish Medical Products Agency (MPA), also known as Läkemedelsverket, is the regulatory body in charge of regulating the approval and distribution of dermatology medications in Sweden. The MPA is in charge of assessing the efficacy and safety of medical products, such as prescription and over-the-counter medicines and making sure they comply with Swedish and EU regulations. Additionally, the agency oversees the post-marketing security of approved products and offers advice to the general public and healthcare professionals on how to use medical products safely.

The Swedish National Board of Health and Welfare (Socialstyrelsen), which oversees the reimbursement of dermatology medications, is located in Sweden. The Board is in charge of deciding which medications fall under the national healthcare system of the nation and are therefore eligible for reimbursement. A drug must fulfil certain requirements, such as being deemed necessary for the treatment of a particular condition, being cost-effective, and being approved for use in Sweden, in order to be eligible for reimbursement.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.